Kura Oncology, Inc. (FRA:KUR)

Germany flag Germany · Delayed Price · Currency is EUR
7.18
+0.09 (1.21%)
At close: Feb 20, 2026
Market Cap624.86M -7.5%
Revenue (ttm)88.66M
Net Income-184.85M
EPS-2.11
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume223
Open7.18
Previous Close7.10
Day's Range7.18 - 7.18
52-Week Range4.68 - 10.78
Betan/a
RSI51.02
Earnings DateFeb 26, 2026

About Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for ... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Troy Wilson
Employees 192
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol KUR
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements